Immune Checkpoint Inhibitors to Treat Malignant Lymphomas

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Neoplastic cells exhibit genetic and epigenetic diversity, often evading host immune responses and contributing to treatment resistance.
• Tumorigenesis is influenced by patient-specific factors and intratumoral genetic heterogeneity, complicating therapeutic strategies.
• While advancements in hematologic treatment exist, many diseases remain incurable, highlighting the need for novel therapeutic approaches.

Purpose of the Study:

• To review current knowledge on immune checkpoint functions.
• To discuss the impact of immune checkpoints on developing novel antineoplastic treatments.
• To examine the application of anti-CTLA-4 and PD-1/PD-L1 monoclonal antibodies in malignant lymphomas.

Main Methods:

• Literature review focusing on immune checkpoint inhibitors.
• Analysis of genetic and epigenetic factors in neoplastic cells.
• Examination of clinical data regarding monoclonal antibody therapies.

Main Results:

• Immune checkpoints, such as CTLA-4 and PD-1, play a critical role in regulating immune responses against cancer.
• Immunotherapy with checkpoint inhibitors has shown promising antitumor activity in various malignancies.
• Monoclonal antibodies targeting CTLA-4 and PD-1/PD-L1 pathways are emerging as effective treatments for malignant lymphomas.

Conclusions:

• Immune checkpoint blockade represents a significant advancement in cancer immunotherapy.
• Targeting CTLA-4 and PD-1/PD-L1 pathways offers a promising strategy for overcoming treatment resistance in malignant lymphomas.
• Further research into immune checkpoint function will likely lead to more effective antineoplastic therapies.